Login to Your Account

New rare diseases leader emerges as Shire agrees to $32B Baxalta buy

By Nuala Moran
Staff Writer

Monday, January 11, 2016

LONDON – Shire plc has overcome an initial rejection to agree a $32 billion takeover of Baxalta Inc. at $45.57 per share, a 37.5 percent premium to the price when Shire's intentions were first made public on Aug. 4, 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription